These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6756894)

  • 1. Oral administration of peptides.
    Saffran M
    Endocrinol Exp; 1982 Nov; 16(3-4):327-33. PubMed ID: 6756894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency.
    Liang JF; Yang VC
    Biochem Biophys Res Commun; 2005 Sep; 335(3):734-8. PubMed ID: 16115469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic barriers for GI peptide and protein delivery.
    Woodley JF
    Crit Rev Ther Drug Carrier Syst; 1994; 11(2-3):61-95. PubMed ID: 7600588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse.
    Maron R; Guerau-de-Arellano M; Zhang X; Weiner HL
    J Autoimmun; 2001 Feb; 16(1):21-8. PubMed ID: 11221993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of chitosan for the oral administration of peptides.
    Prego C; Torres D; Alonso MJ
    Expert Opin Drug Deliv; 2005 Sep; 2(5):843-54. PubMed ID: 16296782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs.
    Petrus AK; Fairchild TJ; Doyle RP
    Angew Chem Int Ed Engl; 2009; 48(6):1022-8. PubMed ID: 19072807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some approaches to improve bioavailability of peptides and proteins through oral and other mucosal routes.
    Vyas SP; Venugopalan P; Sood A; Mysore N
    Pharmazie; 1997 May; 52(5):339-45. PubMed ID: 9183784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The world of beta- and gamma-peptides comprised of homologated proteinogenic amino acids and other components.
    Seebach D; Beck AK; Bierbaum DJ
    Chem Biodivers; 2004 Aug; 1(8):1111-239. PubMed ID: 17191902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the oral route possible for peptide and protein drug delivery?
    Morishita M; Peppas NA
    Drug Discov Today; 2006 Oct; 11(19-20):905-10. PubMed ID: 16997140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Auxiliary agents for the peroral administration of peptide and protein drugs: synthesis and evaluation of novel pepstatin analogues.
    Kratzel M; Hiessböck R; Bernkop-Schnürch A
    J Med Chem; 1998 Jun; 41(13):2339-44. PubMed ID: 9632367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifunctional matrices for oral peptide delivery.
    Bernkop-Schnürch A; Walker G
    Crit Rev Ther Drug Carrier Syst; 2001; 18(5):459-501. PubMed ID: 11763498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of oral bioavailability of insulin in humans.
    Badwan A; Remawi M; Qinna N; Elsayed A; Arafat T; Melhim M; Hijleh OA; Idkaidek NM
    Neuro Endocrinol Lett; 2009 Mar; 30(1):74-8. PubMed ID: 19300394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
    Stoev S; Cheng LL; Manning M; Wo NC; Szeto HH
    J Pept Sci; 2006 Sep; 12(9):592-604. PubMed ID: 16625682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs.
    Takeuchi H; Matsui Y; Sugihara H; Yamamoto H; Kawashima Y
    Int J Pharm; 2005 Oct; 303(1-2):160-70. PubMed ID: 16125348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides.
    Kamei N; Morishita M; Takayama K
    J Control Release; 2009 Jun; 136(3):179-86. PubMed ID: 19250953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New absorption promoter for the buccal delivery: preparation and characterization of lysalbinic acid.
    Starokadomskyy PL; Dubey IY
    Int J Pharm; 2006 Feb; 308(1-2):149-54. PubMed ID: 16386392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins.
    Kolmar H
    Curr Opin Pharmacol; 2009 Oct; 9(5):608-14. PubMed ID: 19523876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs.
    Föger F; Kopf A; Loretz B; Albrecht K; Bernkop-Schnürch A
    Amino Acids; 2008 Jun; 35(1):233-41. PubMed ID: 17726639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.